Integrated Specific Pathogen Free Research Models and Human New Approach Methodologies to Advance HIV/AIDS Research (U42 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Assistance Listings: 93.351 -- Research Infrastructure Programs
Description
This NOFO is issued during a period of accelerating development, validation, and adoption of human new approach methodologies (NAMs). Accordingly, it has two integrated priorities for NIH-funded HIV/AIDS research: (1) implementation of a NAMs-enabled stewardship framework, including optional HIV-relevant human in vitro testing support and pilot benchmarking activities, to reduce or replace specific pathogen free (SPF) in vivo model use where scientifically appropriate without compromising rigor, reproducibility, or translational relevance; and (2) support for high-quality SPF colony resources for studies in which well-characterized in vivo models remain scientifically necessary.
Under the NAMs-enabled component, required elements include: (1) integration of a NAMs triage and consultation service within request intake and allocation workflows to identify NAM-feasible studies and document reductions or replacements in in vivo use; and (2) establishment of a formal referral pathway to NAM centers as well as human tissue and other human science based resources to facilitate collaborative HIV-relevant human NAM development, benchmarking, and refinement. Applicants may also propose optional NAMs-enabled HIV human in vitro testing support (research use only), including standardized operating procedures, quality control frameworks, and user guidance for viral load quantification, drug resistance assessment, and ex vivo susceptibility assays, as well as optional pilot benchmarking projects to define performance metrics, quality control benchmarks, and context-of-use statements for HIV-relevant human NAMs.
Under the SPF resource component, the award will support core colony operations, including colony management and husbandry; transparent, merit-based request intake and allocation; comprehensive virologic surveillance and rapid mitigation to preserve SPF status; and high-resolution immunogenetic characterization (e.g., MHC typing) to enable rigorous, genotype-informed study design and efficient stewardship of limited in vivo resources.
Eligibility
Eligible applicants
Government
- State governments
- Public and Indian housing authorities
- County governments
- City or township governments
- Federally recognized Native American tribal governments
- Special district governments
Education
- Private institutions of higher education
- Independent school districts
- Public and state institutions of higher education
Nonprofit
- Nonprofits non-higher education without 501(c)(3)
- Nonprofits non-higher education with 501(c)(3)
- Other Native American tribal organizations
Business
- Small businesses
- For-profit organizations other than small businesses
Miscellaneous
- Other
Additional information
Grantor contact information
Description
ORIPDCM@mail.nih.gov
Documents
No documents are currently available.
Link to additional information
--
Forecasted
Estimated Post Date:
November 24, 2026
Estimated Application Due Date:
January 25, 2027
Estimated Due Date Description:
Not available
Estimated Award Date:
February 1, 2028
Estimated Project Start Date:
February 1, 2028
Fiscal Year:
2028
Award
$--
Program Funding
4
Expected awards
$212,004
Award Minimum
$2,725,311
Award Maximum
Funding opportunity number:
PAR-28-019
Cost sharing or matching requirement:
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Health
Category Explanation:
History
Version:
1
Forecast posted date:
May 20, 2026
Archive date:
--
